Kyle Lefkoff insider trades: Array Biopharma (ARRY) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kyle reports to the SEC
Open-market buys and sales
26 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 6, 2019 | ARRY | ↓ Sell | 25,000 | $20.51 | $513K | Direct | Feb 8, 2019 (2d) |
| Feb 6, 2019 | ARRY | ↓ Sell | 10,000 | $20.84 | $208K | Indirect | Feb 8, 2019 (2d) |
| Jul 6, 2018 | ARRY | ↓ Sell | 50,000 | $17.45 | $873K | Direct | Jul 6, 2018 (0d) |
| Feb 9, 2018 | ARRY | ↓ Sell | 50,000 | $17.01 | $851K | Direct | Feb 12, 2018 (3d) |
| Sep 29, 2017 | ARRY | ↓ Sell | 38,865 | $12.31 | $478K | Direct | Sep 29, 2017 (0d) |
| Mar 31, 2017 | ARRY | ↓ Sell | 45,000 | $8.92 | $401K | Direct | Apr 4, 2017 (4d) |
| Mar 10, 2017 | MGEN | ↓ Sell | 5,800 | $14.34 | $83K | Indirect | Mar 13, 2017 (3d) |
| Mar 8, 2017 | MGEN | ↓ Sell | 15,000 | $15.40 | $231K | Indirect | Mar 8, 2017 (0d) |
| Feb 28, 2017 | MGEN | ↓ Sell | 10,258 | $13.89 | $143K | Indirect | Feb 28, 2017 (0d) |
| Feb 23, 2017 | MGEN | ↓ Sell | 5,902 | $14.14 | $83K | Indirect | Feb 24, 2017 (1d) |
| Mar 3, 2015 | ARRY | ↓ Sell | 70,000 | $8.00 | $560K | Direct | Mar 4, 2015 (1d) |
| Jul 30, 2013 | RALY | ↓ Sell | 1,171,248 | $23.54 | $27.6M | By Boulder Ventures IV (Annex), L.P. | Aug 1, 2013 (2d) |
| Jul 30, 2013 | RALY | ↓ Sell | 158,445 | $23.54 | $3.7M | By Boulder Ventures V, L.P. | Aug 1, 2013 (2d) |
| Jul 30, 2013 | RALY | ↓ Sell | 76,954 | $23.54 | $1.8M | By Boulder Ventures IV, L.P. | Aug 1, 2013 (2d) |
| Jul 10, 2013 | RALY | ↓ Sell | 1,861 | $24.81 | $46K | By Boulder Ventures IV (Annex), L.P. | Jul 12, 2013 (2d) |
| Jul 10, 2013 | RALY | ↓ Sell | 124 | $24.81 | $3K | By Boulder Ventures IV, L.P. | Jul 12, 2013 (2d) |
| Aug 11, 2011 | ARRY | ↑ Buy | 5,000 | $2.22 | $11K | In 401k Profit Sharing Plan | Aug 11, 2011 (0d) |
| Nov 18, 2010 | ARRY | ↓ Sell | 10,000 | $3.27 | $33K | Direct | Nov 18, 2010 (0d) |
| May 7, 2010 | ARRY | ↑ Buy | 4,000 | $3.71 | $15K | In 401k Profit Sharing Plan | May 11, 2010 (4d) |
| Nov 13, 2008 | ARRY | ↑ Buy | 3,000 | $3.28 | $10K | In profit sharing account | Nov 13, 2008 (0d) |
| Mar 10, 2008 | ARRY | ↑ Buy | 3,000 | $5.39 | $16K | In profit sharing account | Mar 12, 2008 (2d) |
| Mar 10, 2008 | ARRY | ↑ Buy | 2,000 | $5.38 | $11K | By self as UTMA custodian for sons | Mar 12, 2008 (2d) |
| Nov 9, 2006 | ARRY | ↓ Sell | 45,000 | $11.67 | $525K | Direct | Nov 9, 2006 (0d) |
| Nov 9, 2006 | ARRY | ↓ Sell | 6,000 | $11.93 | $72K | As UGMA custodian for minor children | Nov 9, 2006 (0d) |
| Feb 21, 2006 | ARRY | ↓ Sell | 10,000 | $9.01 | $90K | Direct | Feb 22, 2006 (1d) |
| Feb 21, 2006 | ARRY | ↓ Sell | 1,000 | $9.16 | $9K | As UGMA custodian for minor child | Feb 22, 2006 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Kyle Lefkoff's insider trades
Kyle Lefkoff is a director at Array Biopharma (ARRY). Since Feb 21, 2006, Kyle has reported 5 open-market purchases worth $63K and 21 sales worth $38.3M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (14 filings), option exercises (10 filings), gifts (7 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARRY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.